FY2030 Earnings Forecast for Imunon Issued By HC Wainwright

Imunon, Inc. (NASDAQ:IMNN) – Analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Imunon in a research report issued on Thursday, February 5th. HC Wainwright analyst E. Bodnar expects that the company will earn ($1.45) per share for the year. The consensus estimate for Imunon’s current full-year earnings is ($1.68) per share.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.57.

Other equities research analysts have also issued reports about the stock. Brookline Capital Acquisition restated a “buy” rating on shares of Imunon in a report on Wednesday, January 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $232.50.

Imunon Stock Up 6.5%

Shares of Imunon stock opened at $3.27 on Friday. Imunon has a 52-week low of $2.99 and a 52-week high of $41.22. The company has a market capitalization of $10.04 million, a P/E ratio of -0.34 and a beta of 2.14. The company has a 50 day moving average of $3.67 and a 200 day moving average of $4.90.

Hedge Funds Weigh In On Imunon

An institutional investor recently raised its position in Imunon stock. Riverview Capital Advisers LLC lifted its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 193.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,364 shares of the company’s stock after acquiring an additional 22,649 shares during the period. Riverview Capital Advisers LLC owned 1.41% of Imunon worth $176,000 at the end of the most recent reporting period. Institutional investors own 4.47% of the company’s stock.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.